PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.18%
Revenue growth of 2.18% vs. zero growth in Healthcare. Walter Schloss might still want to see if it can translate into profits.
-22.45%
Negative gross profit growth while Healthcare median is 0.00%. Seth Klarman would suspect poor product pricing or inefficient production.
-866.94%
Negative EBIT growth while Healthcare median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-866.94%
Negative operating income growth while Healthcare median is -0.54%. Seth Klarman would check if structural or cyclical issues are at play.
-1775.75%
Negative net income growth while Healthcare median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-1785.39%
Negative EPS growth while Healthcare median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-1785.39%
Negative diluted EPS growth while Healthcare median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
11.26%
Share change of 11.26% while Healthcare median is zero. Walter Schloss would see if the modest difference matters long-term.
11.07%
Diluted share change of 11.07% while Healthcare median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
90.83%
OCF growth of 90.83% while Healthcare is zero. Walter Schloss might see a modest positive difference, which can compound over time.
68.66%
FCF growth of 68.66% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
4893.26%
5Y CAGR of 4893.26% while Healthcare is zero. Walter Schloss might see a slight improvement that could compound if momentum builds.
1224.22%
3Y CAGR of 1224.22% while Healthcare median is zero. Walter Schloss might see a modest improvement overshadowing the broader sector’s stagnation.
-1227.10%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
15.30%
OCF/share CAGR of 15.30% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
-7393.93%
Negative 3Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-5688.60%
Negative 10Y net income/share CAGR vs. Healthcare median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
-3007.60%
Negative 5Y CAGR while Healthcare median is 0.00%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-1597.85%
Negative 3Y CAGR while Healthcare median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
5422.95%
Equity/share CAGR of 5422.95% while Healthcare median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
2128.90%
5Y equity/share CAGR > 1.5x Healthcare median of 3.50%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
211.19%
3Y equity/share CAGR > 1.5x Healthcare median of 1.75%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-37.46%
AR shrinking while Healthcare median grows. Seth Klarman sees potential advantage unless it signals declining demand.
13.05%
Inventory growth of 13.05% while Healthcare median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
-7.26%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-14.39%
Negative BV/share change while Healthcare median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-17.06%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
-21.64%
R&D dropping while Healthcare median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
2.01%
SG&A dropping significantly vs. Healthcare median. Joel Greenblatt sees near-term margin upside but checks for underinvestment risk.